Faith Charles Acquires 7,100 Shares of CNS Pharmaceuticals (NASDAQ:CNSP) Stock

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) Director Faith Charles acquired 7,100 shares of CNS Pharmaceuticals stock in a transaction dated Monday, May 18th. The shares were bought at an average cost of $4.79 per share, with a total value of $34,009.00. Following the transaction, the director owned 7,100 shares in the company, valued at approximately $34,009. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

CNS Pharmaceuticals Stock Performance

Shares of CNSP stock traded up $0.02 during trading hours on Wednesday, hitting $4.80. 17,424 shares of the company were exchanged, compared to its average volume of 938,792. The firm has a market cap of $3.88 million, a P/E ratio of -0.16 and a beta of 2.62. CNS Pharmaceuticals, Inc. has a fifty-two week low of $1.90 and a fifty-two week high of $15.73. The company has a 50 day simple moving average of $3.25 and a two-hundred day simple moving average of $4.86.

CNS Pharmaceuticals (NASDAQ:CNSP) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($7.30) EPS for the quarter, topping the consensus estimate of ($8.82) by $1.52.

Hedge Funds Weigh In On CNS Pharmaceuticals

A number of large investors have recently modified their holdings of the company. Ikarian Capital LLC bought a new position in CNS Pharmaceuticals in the 4th quarter valued at about $241,000. Boothbay Fund Management LLC bought a new position in CNS Pharmaceuticals in the 4th quarter valued at about $71,000. Finally, Armistice Capital LLC bought a new position in CNS Pharmaceuticals in the 2nd quarter valued at about $335,000. 14.02% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of CNS Pharmaceuticals in a research report on Monday, April 20th. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $20.00.

CNS Pharmaceuticals Company Profile

CNS Pharmaceuticals, Inc, headquartered in Houston, Texas, is a clinical-stage biopharmaceutical company focused on developing therapies for aggressive central nervous system tumors. The company’s lead candidate, berubicin, is an anthracycline derivative engineered to cross the blood-brain barrier for the treatment of glioblastoma multiforme and other brain cancers. In addition to berubicin, CNS Pharmaceuticals is advancing WP1066, an immunotherapy agent designed to inhibit the STAT3 signaling pathway and enhance anti-tumor immune activity in the tumor microenvironment.

Berubicin has completed a Phase 1 clinical trial in patients with recurrent glioblastoma, where it demonstrated proof-of-concept signals, and is currently in Phase 2 development.